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Purpose: To describe changes in HRQoL of pulmonary tuberculosis (PTB) patient and illustrate impact 
of malnutrition and Type II diabetes on relapse of PTB. 
Case: A Chinese male patient with complaints of productive cough, and loss of weight and appetite was 
registered; sputum smear confirmed that patient had PTB. Diagnosis was also supported by routine 
investigations. Patient had past history of PTB and Type II diabetes mellitus. For management of 
secondary tuberculosis, he was prescribed WHO recommended therapy. Elevated HbA1c levels and 
history of drop-off serum albumin concentration at the start of treatment demonstrated inappropriate 
glycaemic control and malnutrition over the past months. SF-36v2 was used to estimate HRQoL scores 
at start, after two months and at the end of TB therapy. Although patient’s perception of mental and 
physical health improved with progress of treatment, vitality (VT), social functioning (SF) and role 
emotion (RE) scores were still lower than Malaysian norms. Patient was declared ‘cured’ but state of 
‘health’ as defined by WHO was not achieved.   
Conclusion: Relapse of PTB might be a consequence of inappropriate glycaemic control and 
malnutrition. This case report demonstrates the need for more comprehensive efforts at TB programs to 
improve HRQoL of TB patients. 
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INTRODUCTION 
 
Tuberculosis (TB) is a public health tragedy 
with an annual incidence rate of around 9 
million cases worldwide. TB treatment is quite 
difficult for patients and providers because of 
the chronic nature of the disease. DOTS 
(Directly observed treatment short course) 
strategy was adopted in the mid-1990s as a 
basis of tuberculosis control. In this strategy, 
isoniazid (H), pyrazinamide (Z), rifampicin 
(R), ethambutol (E), streptomycin (S) are 
recommended as first-line treatment [1]. 
Outcome of tuberculosis treatment is 
reported on the basis of categories (Table 1) 
developed and recommended by a working 
group of WHO and International Union 
against Tuberculosis and Lung Disease 
(IUATLD) [1]. 
 
Relapse of tuberculosis is a situation 
whereby a patient becomes and remains 
culture-negative while receiving anti-
tuberculosis drugs but develops active 
tuberculosis again after completion of 
treatment [2]. Chang et al [3] reported 
diabetes as one of the significant risk factors 
for pulmonary tuberculosis relapse.  
Health Related Quality of Life (HRQoL) can 
be defined as person’s perception of his or 
her physical or mental health. It covers broad 
domains including physical, psychological, 
economic, spiritual and social wellbeing [4].  
 
SF-36 is a generic HRQoL questionnaire and 
consists of 36 items covering 8 dimensions 
(sub-scales): Physical function (PF), Role 
physical (RP), Bodily pain (BP), General 
health (GH), Vitality (VT), Social function 
(SF), Role emotional (RE) and Mental health 
(MH). Each dimension scores from 0 to 100 
(with 100 being the best score and 0 the 
worst). The scales can be aggregated to two 
summary measures Physical Component 
Summary (PCS) and Mental Component 
Summary (MCS) [5]. SF-36 is a reliable and 
valid tool to access HRQoL both in non-
clinical and diseased population [5]. 
 
We discuss in this report a relapse case of 
pulmonary tuberculosis. Patient was diabetic 
for the preceding ten years. Glycaemic 
control of patient was poor. HRQoL was 
assessed at three different time points (start 
of therapy, at the end of intensive phase and 
at the end of treatment) using a licensed SF-
36v2 questionnaire.  
 
Table 1: Tuberculosis treatment outcome categories according to WHO and IUATLD recommendations 
 
Outcome Definition 
Cure  A patient whose sputum smear or culture was positive at the beginning of the 
treatment but who was smear- or culture-negative in the last month of 
treatment and on at least one previous occasion. 
Treatment completed A patient who completed treatment but who does not have a negative sputum 
smear or culture result in the last month of treatment and on at least one 
previous occasion. 
Treatment failure A patient whose sputum smear or culture is positive at 5 months or later 
during treatment. Also included in this definition are patients found to harbor a 
multidrug-resistant (MDR) strain at any point of time during the treatment, 
whether they are smear-negative or -positive.  
Died A patient who dies for any reason during the course of treatment. 
Default  A patient whose treatment was interrupted for 2 consecutive months or more. 
Transfer out A patient who has been transferred to another recording and reporting unit 
and whose treatment outcome is unknown. 
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Table 2: Health Related Quality of Life (HRQoL) scores at three different time points of TB treatment 
 
Time point PF RP BP GH VT SF RE MH PCS MCS 
Start of treatment 40 50 31 40 38 50 58 40 36 36 
After 2 months of treatment 80 81 62 62 56 63 92 75 47 49 




A 58 year old Chinese male patient (weighing 
54 kg) visited a primary health care unit with 
complaints of productive cough, and loss of 
weight and appetite for more than one month. 
He was referred to a chest clinic, where his 
sputum smear was found to be positive (S 
+1, 1-9 acid fast bacilli/100 fields) for acid 
fast bacilli (AFB). Chest radiograph showed 
bilateral apical pleural thickening and right 
middle zone consolidation. Erythrocyte 
sedimentation rate (ESR) of patient was 
elevated to 80 mm/h. Albumin concentration 
was 30 g/L. He had a past history of 
pulmonary tuberculosis (PTB) for which he 
was treated for 9 months and declared cured. 
Ten years earlier, he was diagnosed with 
Type II diabetes for which he was placed on 
gliclazide (160 mg) and metformin (1 g) 
tablets, 2 times a day. At the time of 
registration as a relapse TB patient, his 
fasting blood glucose and HbA1c levels were 
10.7 mmol/L and 12.9 %, respectively. With 
all these findings, he was diagnosed as 
sputum smear confirmed case of pulmonary 
tuberculosis. Drugs prescribed for intensive 
phase (IP) of TB treatment were isoniazid 
(225 mg), rifampicin (450 mg), pyrazinamide 
(1200 mg), ethambutol (825 mg) (in fixed 
dose combination) and vitamin B6 (10 mg), 
administered once a day for two months at a 
primary health care unit. Culture and 
sensitivity results confirmed absence of 
resistant Mycobacterium strains to standard 
quadruple chemotherapy.  
 
After two months of IP treatment, patient’s 
sputum was negative for AFB and his cough 
was completely resolved. He also gained 1 
kg of weight. Chest x-ray showed haziness in 
the middle zone of right lung. No data on 
ESR, albumin concentration and fasting 
blood glucose were available. At this 
moment, patient’s therapy was converted to 
continuation phase (CP) for which he was 
prescribed isoniazid (250 mg), rifampicin (600 
mg) and vitamin B6 (10 mg) daily for 7 
months at the primary health care unit. 
Haziness in the middle zone of right lung was 
resolved after 4 months of continuation 
phase. At the closing stage of therapy (9 
months), patient was unable to produce 
sputum; therefore, sputum smear 
examination for AFB was not done. However, 
his fasting blood glucose was 11.9 mmol/L, 
which is well above the acceptable limit.  
 
Table 2 shows HRQoL scores. Patient was 
asked to fill a self-administered SF-36v2 
questionnaire (Mandarin version) at three 
different time points. Obtained responses 
were entered in scoring software version 4 




Incidence and exacerbation of TB are 
positively associated with malnutrition and 
diabetes. Malnutrition and diabetes mellitus 
can render the immune system more 
vulnerable to invading microorganisms such 
as Mycobacterium tuberculosis. Wang et al 
[6] reported that in hyperglycemia, alveolar 
macrophages have less H2O2 (hydrogen 
peroxide) and are less activated. Diabetes 
also affects chemotaxis of monocytes and 
antigen presentation by phagocytes in 
response to Mycobacterium tuberculosis. 
Past medical history of patient was 
suggestive of poor glycaemic control and 
decreased albumin concentration. After 
relapse, his fasting blood glucose levels at 
start and end of TB therapy were still 
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uncontrolled. At the time of registration, 
elevated HbA1c (12.9 %) suggested poor 
glycaemic control over the past months.  
 
One of the major factors for poor glycaemic 
control during TB treatment is drug 
interaction between rifampicin and the 
sulfonylureas.  Rifampicin is an inducer of 
cytochrome P450 enzyme that decreases 
sulfonylurea serum concentrations [7]. 
Rifampicin can also cause early-phase 
hyperglycemia with associated 
hyperinsulinaemia. These effects of 
rifampicin on glycaemic control require 
careful monitoring with appropriate dose 
adjustment of anti-diabetic agents.  
 
In the present case, SF-36v2 scores at the 
start of therapy were lower than reported by 
Azman et al [8] for Malaysian normal 
population. This finding is consistent with 
previously reported studies stating that 
HRQoL is adversely affected in chronic 
illness such as TB [9]. At the end of IP (after 
2 months), improvement in HRQoL scores 
had been observed which was attributed to 
improvement in clinical signs and symptoms. 
However, BP, VT and SF scales were still 
below Malaysian norms suggesting that the 
patient was still experiencing body pain, had 
difficulty in performing routine activities with 
minimal participation in social activities. Body 
pain and difficulty in performing routine 
activities might be a consequence of 
hyperglycemia and malnutrition status.  At 
this stage, PCS and MCS scores were also 
less than United States 1998 norms. At the 
end of TB treatment, SF-36v2 scores showed 
improvement but VT, SF and RE were still 
below Malaysian norms. PCS scores at the 
end of therapy were slightly above US norms 
but MCS scores demonstrated negative 
emotions. These negative emotions might be 
due to perceived stigma and lack of 
tuberculosis knowledge [10]. WHO defines 
“health” as a state of complete physical, 
mental and social well-being and not merely 
the absence of disease or infirmity [11]. In the 
present case, although there is evidence that 





Relapse of pulmonary tuberculosis might be 
due to poor glycaemic control and 
malnutrition. There is a strong need to 
document diabetes monitoring parameters in 
medical records of TB patients so that their 
therapies can be tailored according to their 
clinical conditions. Establishment of TB-
diabetes clinic can give more promising 
results in achieving successful treatment 
outcome of co-morbid TB patients. This case 
report demonstrates the need for more 
comprehensive efforts of TB programs to 
improve HRQoL of TB patients. Besides 
providing the prescribed treatment, DOTS 
providers and health managers should 
identify and address emotional, physical and 
societal impact of tuberculosis. SF 36v2 can 
be used to monitor the progress of treatment 
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